Rhinosinusitis

IDSA Rhinosinusitis Guidelines

IDSA Rhinosinusitis GUIDELINES App brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/88047

Contents of this Issue

Navigation

Page 8 of 11

Table 5. Antimicrobial Regimens for ABRS in Children Indication First Line (daily dose) Initial empirical therapy Amoxicillin-clavulanate (45 mg/kg/day PO bid) β-lactam allergy Type I hypersensitivity Non-type I hypersensitivity Risk for antibiotic resistance or Second Line (daily dose) > Amoxicillin-clavulanate (90 mg/kg/day PO bid) > Levofloxacin (10-20 mg/kg/day PO q12-24h) > Clindamycina (30-40 mg/kg/day PO tid) plus cefixime (8 mg/kg/day PO bid) or cefpodoxime (10 mg/kg/day PO bid) > Amoxicillin-clavulanate (90 mg/kg/day PO bid) Failed initial therapy > Clindamycina (30-40 mg/kg/day PO tid) plus cefixime (8 mg/kg/day PO bid) or cefpodoxime (10 mg/kg/day PO bid) Severe infection requiring hospitalization > Ampicillin/sulbactam (200-400 mg/kg/day IV q6h) > Ceftriaxone (50 mg/kg/day IV q12h) > Cefotaxime (100-200 mg/kg/day IV q6h) > Levofloxacin (10-20 mg/kg/day IV q12-24h) a Resistance to clindamycin (~31%) is found frequently among S. pneumoniae serotype 19A isolates in different parts of the USA. > Levofloxacin (10-20 mg/kg/day PO q12-24h)

Articles in this issue

Archives of this issue

view archives of Rhinosinusitis - IDSA Rhinosinusitis Guidelines